A Randomized, Double-blind, Placebo-controlled, Two-Way Crossover Study to Evaluate the Safety, Tolerability and Clinical Activity of ASM-024 Administered by Dry Power Inhalation to Patients With GOLD 2 (Moderate) or GOLD 3 (Severe) Chronic Obstructive Pulmonary Disease (COPD)
Phase of Trial: Phase II
Latest Information Update: 18 Dec 2014
At a glance
- Drugs ASM 024 (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Sponsors Asmacure
- 15 Dec 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 07 Aug 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 21 Jul 2014 Planned End Date changed from 1 Sep 2014 to 1 Jan 2015 as reported by ClinicalTrials.gov.